Will BL-B01D1 Phase 3 trial NCT06382129 report a statistically significant primary overall-survival difference by 29 June 2027? · 85% NO — LiveFuture
Open on LiveFuture.ai →

Will BL-B01D1 Phase 3 trial NCT06382129 report a statistically significant primary overall-survival difference by 29 June 2027?

Will BL-B01D1 Phase 3 trial NCT06382129 report a statistically significant primary overall-survival difference by 29 June 2027?

Status: Active · Outcome: Pending

Resolution date:

Resolution criteria

Resolution authority: the ClinicalTrials.gov results record at https://clinicaltrials.gov/study/NCT06382129. Trial: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02). Prespecified primary outcome: Overall survival (OS); time frame: Up to approximately 24 months. Randomized arms: BL-B01D1 and Docetaxel. Resolves YES if a statistical comparison explicitly attached to this primary outcome and these two arms posts a numeric, two-sided, multiplicity-adjusted p-value below 0.05 by 29 June 2027. Where the registry explicitly declares a single primary comparison without multiplicity adjustment, its declared two-sided p-value is used. Secondary outcomes, one-sided tests, within-arm comparisons, interim analyses and undefined p-value qualifiers cannot satisfy YES. Resolves NO if no qualifying primary analysis is publicly posted by the deadline, including negative or absent results. An ambiguous analysis, unspecified sidedness or revised primary endpoint goes to manual review. Significance does not establish treatment benefit, approval or clinical suitability. Completion estimate at birth: 2026-12; source-native precision retained.

Resolution source